United States: Opinion: 2024 Will Be A Buyers' Market In Biopharma. It Already Is. - Lowenstein Sandler

The sale of listed contract drugmaker Catalent to Novo Nordisk last week follows Johnson & Johnson's recent agreement to acquire Ambrx Biopharma for $2 billion...